Desumab-loaded artificial bone and preparation method thereof

A technology of denosumab and artificial bone, applied in pharmaceutical formulations, prostheses, drug delivery, etc., can solve the problem of not being able to inhibit tumors, and achieve the effects of inhibiting bone resorption, inhibiting tumor cells, and improving bone quality

Active Publication Date: 2022-05-27
THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003]Currently, neither autologous bone, allogeneic bone nor conventional artificial bone has the effect of inhibiting tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Desumab-loaded artificial bone and preparation method thereof
  • Desumab-loaded artificial bone and preparation method thereof
  • Desumab-loaded artificial bone and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] 1. Composite Gel Preparation

[0040] (1) Mixing: After adding Denosumab (120mg) to 100ml of deionized, then adding an appropriate amount of 0.1g ZIF-8 powder for physical mixing to obtain a Denosumab@ZIF-8 suspension, and then adding an appropriate amount of 2g carboxymethyl chitosan, After thorough physical mixing, the CMCS / Denosumab@ZIF-8 mixed gel was obtained, and then an appropriate amount of 4g nano-hydroxyapatite was added, and the CMCS / nHA / Denosumab@ZIF-8 mixed gel was obtained after thorough physical mixing;

[0041] (2) Stirring: use a constant temperature magnetic stirrer to stir evenly, stirring time is 30-60min, temperature is 20-30°C; the mass percentage of carboxymethyl chitosan in the suspension is 32.2%, and the mass percentage of nano-hydroxyapatite is 32.2%. The content was 64.3%, the mass percentage of denosumab was 1.9%, and the mass percentage of ZIF-8 was 1.6%.

[0042] 2. Freeze drying and forming

[0043] (1) Packing: the gel obtained in step...

Embodiment 2

[0051] 1. Composite Gel Preparation

[0052] (1) Mixing: Add Denosumab (360mg) to 100ml of deionized, and then add an appropriate amount of 0.1g 2-methylimidazole zinc salt (ZIF-8) for physical mixing to obtain Denosumab@ZIF-8 suspension, and then add an appropriate amount of 2g of carboxymethyl chitosan, fully physically mixed to obtain CMCS / Denosumab@ZIF-8 mixed gel, and then added an appropriate amount of 4g of nano-hydroxyapatite, and fully physically mixed to obtain CMCS / nHA / Denosumab@ZIF-8 mixed gel glue;

[0053] (2) Stirring: use a constant temperature magnetic stirrer to stir evenly, stirring time is 30-60min, temperature is 20-30°C; the mass percentage of carboxymethyl chitosan in the suspension is 31%, and the mass percentage of nano-hydroxyapatite is 31%. The content was 61.9%, the mass percentage of denosumab was 5.6%, and the mass percentage of ZIF-8 was 1.5%.

[0054] 2. Freeze drying and forming

[0055] (1) Packing: the gel obtained in step (1) is extracted...

Embodiment 3

[0063] 1. Composite Gel Preparation

[0064] (1) Mixing: Add Denosumab (720mg) to 100ml of deionized, and then add an appropriate amount of 0.1g 2-methylimidazole zinc salt (ZIF-8) for physical mixing to obtain Denosumab@ZIF-8 suspension, and then add an appropriate amount of 2g of carboxymethyl chitosan, fully physically mixed to obtain CMCS / Denosumab@ZIF-8 mixed gel, and then added an appropriate amount of 4g of nano-hydroxyapatite, and fully physically mixed to obtain CMCS / nHA / Denosumab@ZIF-8 mixed gel glue;

[0065] (2) Stirring: use a constant temperature magnetic stirrer to stir evenly, stirring time is 30-60min, temperature is 20-30°C; the mass percentage of carboxymethyl chitosan in the suspension is 29.3%, and the mass percentage of nano-hydroxyapatite is 29.3%. The content is 58.7%, the mass percentage content of denosumab is 10.5%, and the mass percentage content of ZIF-8 is 1.5%.

[0066] 2. Freeze drying and forming

[0067] (1) Packing: the gel obtained in ste...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
elastic modulusaaaaaaaaaa
elastic modulusaaaaaaaaaa
elastic modulusaaaaaaaaaa
Login to view more

Abstract

The invention discloses an artificial bone loaded with desumab and a preparation method of the artificial bone. The artificial bone is prepared from carboxymethyl chitosan powder, nano-hydroxyapatite powder, 2-methylimidazole zinc salt and desumab, the mass ratio of the carboxymethyl chitosan powder to the nano hydroxyapatite powder to the 2-methylimidazole zinc salt to the desumab is (2 to 4) to (2 to 4) to (0.05 to 0.2) to (0.12 to 0.72). The artificial bone can be used for treating the osteolytic bone tumor, and plays a biological effect by inhibiting postoperative bone defect local tumor recurrence and metastasis of the osteolytic bone tumor.

Description

technical field [0001] The invention belongs to the field of biomedical materials, and relates to an artificial bone loaded with denosumab and a preparation method thereof. Background technique [0002] Tumor bone defect is a huge bone defect caused by surgery for benign and malignant bone tumors and other diseases, and faces great challenges of difficult repair and tumor recurrence. At present, the commonly used bone repair materials include autologous bone, allogeneic bone and artificial bone. Among them, the source of autologous bone is limited, and it causes secondary trauma to the bone extraction site. Allogeneic bone has the risk of infection and disease, so artificial bone is an important choice. [0003] At present, no matter autologous bone, allogeneic bone, or conventional artificial bone has no tumor suppressing effect. The commonly used anti-tumor chemotherapy drugs and local radiotherapy have huge toxic and side effects. The development of anti-tumor artificia...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L27/20A61L27/12A61L27/22A61L27/50A61L27/54A61L27/56A61L27/58
CPCA61L27/20A61L27/12A61L27/227A61L27/50A61L27/54A61L27/56A61L27/58A61L2430/02A61L2300/256A61L2400/12A61L2300/412A61L2300/416A61L2300/602C08L5/08C08L89/00
Inventor 邓幼文谭伟
Owner THE THIRD XIANGYA HOSPITAL OF CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap